Skip to main content
SAMSUNG PHARMACEUTICAL.CO.,Ltd. logo

SAMSUNG PHARMACEUTICAL.CO.,Ltd. — Investor Relations & Filings

Ticker · 001360 ISIN · KR7001360007 KO Manufacturing
Open in API
Filings indexed 196 across all filing types
Latest filing 2020-02-21 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 001360

About SAMSUNG PHARMACEUTICAL.CO.,Ltd.

http://www.sspharm.com/

Samsung Pharmaceutical Co., Ltd. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products. Its portfolio includes a range of medications, such as antibiotics and liver treatments, with a research focus on therapeutic areas like neoplasms. In addition to its core pharmaceutical operations, the company is also involved in the bio business and the sale of health foods.

Recent filings

Filing Released Lang Actions
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Services Commission and the Korea Exchange. It specifically details a 'Decision on Paid-in Capital Increase' (유상증자결정), which involves the issuance of new shares via third-party allocation. This falls under the category of capital structure changes and share issuance announcements.
2020-02-21 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Financial Services Commission/Korea Exchange regarding the 'Decision to Issue Convertible Bonds' (전환사채권 발행결정). It details the terms of the bond issuance, including interest rates, conversion prices, and the list of investors. This falls under capital structure changes and financing activities, which is classified as 'CAP'.
2020-02-14 Korean
유상증자또는주식관련사채등의발행결과(자율공시)
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory filing from Samsung Pharmaceutical regarding the results of a private placement of convertible bonds. It details the issuance amount, payment date, and security type. Since it describes the issuance of new securities (convertible bonds) and the resulting capital change, it falls under the category of Share Issue/Capital Change.
2020-02-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and pledge agreements of major shareholders (GemVax & KAEL and related parties) in Samsung Pharmaceutical. This falls under the category of Major Shareholding Notification (MRQ) as it tracks significant ownership levels and changes.
2020-01-03 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and contractual relationships (such as pledges) of a major shareholder (GemVax & KAEL) in Samsung Pharmaceutical. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2019-12-05 Korean
합병등종료보고서(합병)
M&A Activity Classification · 100% confidence The document is a '합병등종료보고서' (Report on Completion of Merger), which is a formal regulatory filing in South Korea detailing the finalization of a merger between Samsung Pharmaceutical Co., Ltd. and Samsung Pharmaceutical Healthcare Co., Ltd. It includes the merger schedule, financial impact, and confirmation of completion. This falls under the category of M&A activity (TAR) as it documents the conclusion of a merger transaction.
2019-11-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.